Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Palynziq

- PMLiVE

FDA approves BioMarin’s Roctavian as first gene therapy for severe haemophilia A

Approximately 2,500 patients are expected to be eligible to receive the one-time therapy

Biomarin

BioMarin’s application for haemophilia A gene therapy accepted by FDA

If approved, the treatment would be the first gene therapy in the US for this indication

- PMLiVE

EC approves BioMarin’s gene therapy Roctavian for severe haemophilia A

Approximately 20,000 adults are affected by haemophilia A across more than 70 countries in Europe, the Middle East and Africa

Biomarin

FDA keeps BioMarin’s gene therapy for phenylketonuria on hold

The decision follows data suggesting BioMarin’s experimental gene therapies may have the potential to progress cancers

Biomarin

FDA pauses BioMarin gene therapy trial

The study for BMN 307 in genetic disease phenylketonuria will be paused while malignancies in mice are explored

- PMLiVE

Merck spin-off Organon sees share price jump at Q2 results

Strong growth in women’s health and biosimilars is driving the new company, which expects 2021 growth in the “low to mid-single digit range”

- PMLiVE

Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’

Sales grew by 19% in the second quarter as key products begin to recover from the impact of the pandemic

- PMLiVE

GSK beats expectations thanks to strong vaccine sales in Q2

GSK's vaccine business was up by 39% to £1.6bn thanks to the strong growth (46%) of its meningitis vaccine

- PMLiVE

AZ raises full-year guidance after completing Alexion acquisition in Q2

Total revenue was up by 31% to $8.2bn and also increased by 24% to $15.2bn for the half year

- PMLiVE

Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb

COVID-19 vaccine generated $7.8bn in the second quarter of 2021 alone

- PMLiVE

Novartis sees demand returning to pre-COVID-19 levels in Q2 results

Swiss pharma company also provided key updates on a number of drug candidates in its pipeline

- PMLiVE

Bristol-Myers Squibb’s revenues rise on Celgene acquisition

Sales of immunotherapy Opdivo decreased due to COVID-19 impact

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links